SuperGen, Astex Management Sell Merger Strategy To Investors
This article was originally published in The Pink Sheet Daily
Executive Summary
After announcing a merger of the biotechs, management sought to convince investors the combination offers the best long-term value for both sides during an analyst day.
You may also be interested in...
SuperGen Buys U.K.'s Astex, Building Cash-Rich Oncology Play
The deal brings private Astex a long-sought NASDAQ listing and beefs up cash-rich SuperGen's lackluster pipeline.
Roche Pharma CEO Graham On Growth Prospects, Policy Pressures, Alzheimer’s And More
“I don’t think anybody can afford to not be in the Alzheimer’s race,” Graham said in one of her first public appearances since becoming CEO of Roche pharmaceuticals.
Commercial Fate Of Sarepta’s DMD Gene Therapy Remains Tied To EMBARK
The company guided investors to expect a narrow initial label under a US FDA accelerated approval for SRP-9001, with expansion possible based on EMBARK.